Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1572-1578

  Lindfelt, Tristan ^a   O'Brien, John ^a   Song, Jessica C ^a,b   Patel, Rajul ^b   Winslow, Dean L ^a,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome 2B6 polymorphisms; Efavirenz

Indexed keywords

CYTOCHROME 2B6; CYTOCHROME B6; EFAVIRENZ; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL EVALUATION; CODON; DRUG BLOOD LEVEL; ETHNICITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HISPANIC; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PILOT STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77957670817     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P141     Document Type: Article

References (19)

1. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol Myers Squibb Company, March 2010.
2. Mutlib AE, Chen H, Nemeth GA, Gan LS, Christ D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999;27:1319-33.
3. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007;8:547-58.
4. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome p450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
5. Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 2006;318:345-51.
6. Burger D, van der Heiden I, La Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2005;61:148-54.
7. Lang T, Klein K, Richter T, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004;311:34-43.
8. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516 G→T (*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008;64:357-65.
9. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62:267-75.
10. Xu BY, Guo LP, Lee SS, et al. Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol 2007;13:2100-3.
11. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391-2400.
12. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75. (Pubitemid 32055781)
13. USA QuickFacts. US Census Bureau. http://quickfacts.census.gov/qfd/ states/00000.html (accessed 2010 May 20).
14. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520-9.
15. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003;307:906-22.
16. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997;25:2745-51.
17. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
18. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type-1 infected individuals with cytochrome p4502B6*6 and *6. Clin Infect Dis 2007;45:1230-7.
19. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81:557-66.